- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
AbCellera was founded in 2012 by biomedical researchers Carl Hansen, Véronique Lecault, Kevin Heyries, Daniel Da Costa, Kathleen Lisaingo, and Oleh Petriv. In November 2016, the company received a US$ 645K grant from the Bill & Melinda Gates Foundation to develop a test for tuberculosis. In September 2018, a $10M series A round of funding was closed. In May 2020, a $105M series B round of funding was closed.
In January 2017, AbCellera announced that it would be collaborating with Pfizer to discover and develop antibodies against "undisclosed membrane protein targets.”
In September 2021, the company announced a multi-year agreement with Moderna to develop mRNA -based antibody treatments against multiple diseases.
In January 2022, the company received a $1.5 million grant from the Bill & Melinda Gates Foundation to identify monoclonal antibodies against respiratory syncytial virus (RSV).